This giant REIT is about to get even bigger...and better. Here's why you should consider adding it to your portfolio.
Every October, the Social Security Administration (SSA) announces its annual changes to the Social Security program for the coming year. Below is our analysis of the Social Security changes that were announced in Oct. 2020 to take effect on Jan. 1, 2021, according to the SSA's annual fact sheet. Keep them in mind when you update your Social Security information. For 2021, nearly 70 million Social Security recipients are seeing a 1.3% cost-of-living adjustment (COLA) to their monthly benefits. The adjustment helps benefits keep pace with inflation and is based on the Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W) as calculated by the Bureau of Labor Statistics (BLS).
‘I couldn’t secure the loan on my own until the other house was sold. So I applied for the mortgage with my girlfriend.’
Pinterest (NYSE: PINS) reported second-quarter results on Thursday, July 29, that disappointed investors. Although the company reported better-than-expected revenue and earnings per share, it reported lower-than-estimated monthly active users (MAU), and that's what sent shares crashing down. Pinterest reported revenue growth of 125% in Q2.
Medicare – health insurance that kicks in at 65 — is not free. You can unwittingly send your Medicare Part B premium – the part that covers certain doctors, outpatient care and preventive care — sky-high by poorly planning your income beginning at age 63. Medicare part B premiums are determined by the income you had two years ago, so your 2019 income determines your 2021 premiums, and your income this year will determine premiums in 2023.
The operating unit is now only a shell of its former self, but General Electric is better prepared for its future than its past.
International Business Machines Corporation ( NYSE:IBM ) will increase its dividend on the 10th of September to...
It’s a mixed start to the day for Bitcoin and the broader market. A Bitcoin fall through to sub-$41,500 levels would pressure the broader market and bring support levels into play.
Amazon's stock is getting hit after its latest earnings report. Here are three quick reasons why.
Once, at the end of a long job interview, after discussing everything else under the sun, I asked the interviewer what the pay range was for the position. Her lips thinned; she was clearly offended. She said it wasn’t something the company was comfortable sharing. As frustrating as her response was, it was also typical. Anyone who has ever looked for a job probably has experience with companies being cagey about pay. But often we accept it as the way the negotiation game is played, like it’s a d
Investors may be ignoring mounting evidence that the delta variant of COVID-19 could be more troublesome than it is currently being given credit for on Wall Street.
Ever since Larry Culp arrived at the industrial conglomerate to turn it around, investors have worried about the company’s meager cash flow. Now, that’s not a problem, and bearish analysts have disappeared.
Exxon and Chevron reported strong Q2 earnings but struck contrasting tones on returning more capital the shareholders.
The stock market was off its opening lows Friday morning as the Nasdaq composite took the hardest hit from weakness in Amazon.com.
Think about this for a moment: In each of the previous eight bear markets (i.e., not counting the coronavirus crash of 2020), there was at least one double-digit percentage decline in the S&P 500 within the first three years of bouncing back from the bottom. In five of those eight bounce-back rallies, we witnessed two double-digit percentage dips. In other words, the stock market never rebounds as smoothly as things have been over the past 16 months.
We’re well into the Q2 earnings season and the results coming in show a strong overall performance so far. In fact, according to FactSet, if the S&P 500’s actual growth rate for the quarter hits 74.2% - as appears likely right now - it will amount to the biggest year-over-year earnings growth rate the index has displayed since Q4 2009. It’s a confidence boosting turn of events and a slightly surprising one, as noted by Oppenheimer’s Chief Investment Strategist John Stoltzfus. Stoltzfus believes
(Bloomberg) -- Exxon Mobil Corp.’s knockout second-quarter results did little to entice investors because much of the extra cash coming from soaring energy and petrochemical prices will be used to pay down debt rather than reward shareholders.The oil giant and rival Chevron Corp. swung to their biggest profits since pre-pandemic days, fueled in large part by stellar performances from their chemicals units. But the legacy of 2020’s near-40% jump in net debt was all too clear for Exxon, with Chief
Should you FIRE the 4% spending rule in retirement? My play on words refers to the “Financial Independence, Retire Early” movement, as it applies to the standard retirement spending rule that many financial planners have traditionally recommended. New research has analyzed whether changes need to be made to that rule if you’re planning for a 50-year retirement—which is the avowed goal of some followers of the FIRE movement.
Tilray (NASDAQ: TLRY), the big marijuana operator resulting from the recent merger of the namesake company with the former Aprhia, is a stock on fire this week. The "new" Tilray reported its fourth-quarter fiscal 2021 figures on Wednesday, and they looked awfully sweet. Net revenue rose a sturdy 25% year over year to $142 million (taking into account Aphria's performance as a separate company in the year-ago period).
In this article, we discuss the 15 best high volume stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best High Volume Stocks to Buy Now. In May this year, the chief of the United States Securities and Exchange Commission Chair Gary Gensler appeared […]
Moderna debuted in 2018 with the most lucrative initial public offering in biotech history. To that point, the company had existed for eight years and burned through $1.4 billion with no products to show for it. Unlike other biotech companies, Moderna was touting a drug development platform -- using messenger RNA (mRNA) to deliver protein-making instructions to cells -- rather than any individual therapy.